MEDEZE Achieves Nearly THB 160 Million Net Profit in 9M/2025 “ATMPs Sandbox” Marks a Milestone in Advancing Hope for Disease Treatment

12.11.2025

MEDEZE Achieves Nearly THB 160 Million Net Profit in 9M/2025 “ATMPs Sandbox” Marks a Milestone in Advancing Hope for Disease Treatment

MEDEZE Group Public Company Limited (“MEDEZE”) reported a 9-month net profit of THB 159.95 million for 2025, with total revenue reaching THB 587.99 million. Cord tissue–derived stem cells continue to serve as the company’s primary revenue stream. MEDEZE affirms that the launch of the “ATMPs Sandbox” initiative reinforces national progress and enhances the potential for advanced therapeutic treatments—representing an overall projected economic benefit exceeding THB 260 billion.

Dr. Veerapol Khemarangsan, Chief Executive Officer of MEDEZE, stated that in Q3/2025, the company generated total revenue of THB 181.27 million and net profit of THB 30.54 million. For the first nine months, MEDEZE recorded revenue of THB 587.99 million and net profit of THB 159.95 million. The company’s main revenue source continues to be cord tissue stem cells, accounting for 43% of Q3 revenue and 49% of 9-month revenue.

The company has continued expanding its business through investments in a new sales and marketing building, warehouse, solar cell energy system, and the MEDEZE Plus Auto-Matching Software, laying the foundation for future business growth. MEDEZE has also maintained ongoing communication regarding the ATMPs Sandbox initiative, along with securing GMP certification and Cell Bank standard certification—a significant milestone that benefits both the company and Thailand by improving public awareness and understanding.

The ATMPs Sandbox, a pilot research framework for Advanced Therapy Medicinal Products (ATMPs) such as stem cells, has already approved two ATMP products for designated clinical trial hospitals. The initiative targets approval for at least five medical facilities to conduct ATMP trials in Thailand by 2025, enabling Thai patients to access ATMPs domestically through regulated research pathways. Participating hospitals include Bangrak Medical Center (Department of Disease Control) and Vachira Phuket Hospital, both of which have signed cooperation agreements with MEDEZE. Under this partnership, MEDEZE will support laboratory facilities, manufacturing environments, products, and research funding, subject to approval by relevant ethics committees.

The pilot program focuses on three major disease groups:

Degenerative Disc Disease & Spinal Degeneration
– Utilizing autologous adipose-derived stem cells to regenerate disc tissue, slow degeneration, and reduce chronic pain without surgery.
Dermatology & Aging-Related Skin Conditions
– Applying autologous adipose-derived stem cells to repair skin cells, improve elasticity, reduce wrinkles, and restore skin structure.
Colorectal Cancer
– Implementing immunotherapy approaches, particularly NK cell therapy, to boost immune response against cancer cells.

Following the Ministry of Public Health’s announcement promoting the development of high-value medical technologies—including stem cells, gene therapy, and tissue-engineered products—these efforts align with Thailand’s strategic goal of becoming a Wellness & Medical Hub, expected to deliver national economic benefits of approximately THB 266.7 billion.

MEDEZE Achieves Nearly THB 160 Million Net Profit in 9M/2025 “ATMPs Sandbox” Marks a Milestone in Advancing Hope for Disease Treatment

IR Press Releases